NCT04838444View on ClinicalTrials.gov

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

363

Participants

Timeline

Start Date

April 2, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2031

Conditions
Chikungunya Virus Infection
Interventions
BIOLOGICAL

VLA1553

Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.

Trial Locations (10)

23502

Allliance for Multispecialty Research (AMR), Norfolk

33090

Velocity Clinical Research, Hallandale

37920

Alliance for Multispecialty Research (AMR), Knoxville

40509

Alliance for Multispecialty Research (AMR), Lexington

60602

Accelerated Enrollment Solutions (AES), Chicago

68134

Velocity Clinical Research, Omaha

68803

Velocity Clinical Research, Grand Island

78759

Velocity Clinical Research, Austin

84088

Velocity Clinical Research, West Jordan

85020

Accelerated Enrollment Solutions (AES), Phoenix

All Listed Sponsors
lead

Valneva Austria GmbH

INDUSTRY

NCT04838444 - Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) | Biotech Hunter | Biotech Hunter